I think my purpose is to find the companies that will create drugs that will eventually lead to long-term market value. I believe that the opportunity to buy low and sell high is huge in biotech because of the overall volatility in the biotech stocks. Although there is great risk in some of these stocks, I believe that there are many opportunities that investors pass up because they simply don’t understand what they are investing in. Some investors choose to invest in the sector as “followers”. Long-term investors know it is best to be well researched on a company before making an investment and thus, this is what I seek to provide - a place of information about the biotech sector and its companies. Current Scope of Coverage My focus is on immunotherapy anti-cancer drugs and various forms of metabolic disease. Evaluation Criteria There are a number of criteria that I evaluate when contemplating the long-term success of a company. Firstly, I begin with the management team and its advisers because I believe that knowledge is key in the biotech sector. Companies need the right team in place to drive the research of a drug. I look for a strong balance sheet that will carry them through what they are currently doing. I also take into account the current market price of a stock because this might provide them an out if their cash position isn’t strong should they need cash in the future. Most importantly, I think about the tech and how it is doing in relation to the competition. Is It cutting age and effective? Is it something that will have a path toward approval that is unique (orphan path). Lastly, I take into account whether a company will be able to effectively tap the market it is targeting. We all know companies talk about how big their markets are, but being able to gauge just how much they can tap is sometimes difficult because there a number of variables to account for. Such as cost, competition, method of delivery, ease of use for doctors, level of invasiveness, and the current state of the patients (how necessary is the current treatment). Although there are many more criteria that I take into account, these are the main points I touch on when evaluating a drug.